Stock fact sheet · data as of

Disc Medicine, Inc. (IRON): fair value, margin of safety and Wheel Score

Healthcare · Biotechnology · United States · Speculative / Distressed

Close56.65
GLS fair value2.311 of 9 models
Margin of safety-2356%price above fair value
Wheel Score20Weakout of 100
Health1/9Piotroski F-score
Moat0.8/10GLS 10-year score
Market cap$2.2B692k shares a day
Implied vol.203%near-the-money, 20-60 d
P/E-EPS -6.36
Dividend yieldnone
Beta2.05moves more than the market
Next earnings5 Nov 2026in 20 days (before the open)

Is IRON undervalued?

Disc Medicine, Inc. (IRON) closed at 56.65 on 16 Oct 2026, 2356% above the GLS average fair value of 2.31. 1 of the 1 models that produced a number value the shares below the current price. A gap this wide usually means the market is paying for growth or a story the trailing numbers do not show yet; the models work from filed results, not forecasts, so they are conservative by design.

Only 1 of the nine models produced a value (DCF); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.

The nightly engine files IRON under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for IRON

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF2.31-96%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)19.19-66%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target106.00+87%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: IRON passes 1 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 0.8 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -28.6%, ROE -28.7%, ROA -26.3% - with debt at 0.00 times equity and negative free cash flow.

Disc Medicine, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 15 Sep 2026.

Piotroski F-score1 / 9ROIC-28.6%
GLS Moat0.8 / 10ROE-28.7%
Debt / equity0.00ROA-26.3%
Free-cash-flow yield-9.1%Payout ratio0%
Institutions10 / 10Insiders · Congress1 · 5 / 10

Wheel Score 20: Weak

IRON scores 20 out of 100 on the Wheel Score, in the Weak band (under 50). Value 0/25, Health 2/20, Moat 1/15, Premium 5/20, Stability 12/20. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.

Implied volatility is 203%, far above the range the wheel strategy is built for. The premium looks generous; the Wheel Score gives it only 5 of 20 Premium points because moves of that size can blow through any strike. Chain open interest is 44,201 contracts across all expiries - enough for the wheel at normal size.

Volume runs at 692k shares a day on a market cap of $2.2B, with a beta of 2.05 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 12 of 20.

PartPointsFrom
Value0 / 25-2356% margin of safety
Health2 / 20Piotroski 1/9
Moat1 / 15moat 0.8/10
Premium5 / 20implied volatility 203%
Stability12 / 20692k shares/day, $2.2B cap, beta 2.05

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 5 Nov 2026 (before the open), 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Biotechnology

The 12 companies below are the closest to Disc Medicine, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
FTRE
Fortrea Holdings Inc.
22.7534.64+34%45Weak$2.2B
AUPH
Aurinia Pharmaceuticals Inc.
16.7358.34+71%81Prime$2.2B
HRMY
Harmony Biosciences Holdings, Inc.
38.27105.25+64%77Good$2.2B
NVAX
Novavax, Inc.
12.82--44Weak$2.1B
PHVS
Pharvaris N.V.
30.025.50-445%37Weak$2.1B
VRDN
Viridian Therapeutics, Inc.
18.38--45Weak$2.1B
CLDX
Celldex Therapeutics, Inc.
28.930.2352-12198%41Weak$2.3B
VCEL
Vericel Corporation
40.2520.44-97%54Fair$2.1B
IMNM
Immunome, Inc.
17.407.38-136%33Weak$2.1B
BCRX
BioCryst Pharmaceuticals, Inc.
8.0228.41+72%45Weak$2.0B
MRVI
Maravai LifeSciences Holdings, Inc.
7.072.40-195%31Weak$2.0B
RXRX
Recursion Pharmaceuticals, Inc.
3.74--45Weak$2.0B

⚖ Compare IRON with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about IRON

Is IRON undervalued right now?

No: at 56.65 the stock trades 2356% above the GLS average fair value of 2.31 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.

What is the Wheel Score of IRON and what does it mean?

IRON scores 20 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for IRON?

2.31 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Disc Medicine, Inc. report earnings next?

The next earnings report is due on 5 Nov 2026 (before the open), 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does IRON have listed options, and how liquid are they?

Yes. The nightly snapshot found 220 listed contracts with 44,201 open interest across all expiries and implied volatility of 203% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.